Amplia Therapeutics (ATX) AI Stock Analysis

• Market Cap: $84.66M
• Dividend Yield: N/A
• Average Volume (3M): 1.95M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.14
• Revenue Growth: N/A
• EPS Growth: 4.07%
• Country: AU
• Employees: 1
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.01
• Shares Outstanding: 513,071,660
• 10 Day Avg. Volume: 1,785,511
• 30 Day Avg. Volume: 1,949,518
• PEG Ratio: 0.42
• Price to Book (P/B): 1.02
• Price to Sales (P/S): 5.68
• P/FCF Ratio: -3.12
• Enterprise Value/Market Cap: 0.17
• Enterprise Value/Revenue: 3.88
• Enterprise Value/Gross Profit: 4.11
• Enterprise Value/Ebitda: -2.17
• 1Y Price Target: $0.42
• Price Target Upside: 149.88% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

• Rating: 45 Neutral
• Price Target: AU$0.00 ▼(-100.00% Downside)

Amplia Therapeutics' stock score is primarily influenced by its financial performance and technical analysis. The company shows potential with strong gross margins and revenue growth, but ongoing losses and weak cash flows are significant concerns. Technical indicators suggest a neutral market sentiment, while valuation metrics highlight the typical challenges of a biotech firm in the development phase.

Amplia Therapeutics Business Overview & Revenue Model

Company Description

Amplia Therapeutics Limited, a pharmaceutical company, focuses on development of focal adhesion kinase (FAK) inhibitors for oncology and chronic fibrosis in Australia. The company's product pipeline includes AMP945, an inhibitor of FAK, for pancreatic cancer and idiopathic pulmonary fibrosis, as well as other cancers and fibrotic diseases indications, that has completed Phase I clinical trial; and AMP886 for cancer and fibrotic disease indication. It has a collaboration agreement with the Garvan Institute of Media Research in Sydney. The company was formerly known as Innate Immunotherapeutics Limited and changed its name to Amplia Therapeutics Limited in September 2018. Amplia Therapeutics Limited was incorporated in 2000 and is headquartered in Melbourne, Australia.

How the Company Makes Money

Amplia Therapeutics generates revenue primarily through the development and commercialization of its drug candidates. The company's revenue model includes funding from grants and research partnerships, which support the clinical development of its therapies. Additionally, Amplia may enter into licensing agreements or partnerships with larger pharmaceutical companies, allowing them to share in the development costs and potential profits from successful drug candidates. Revenue can also be derived from milestone payments and royalties based on sales once products are commercialized. Furthermore, the company may attract investment through equity financing to support its ongoing research and development efforts.

Amplia Therapeutics Financial Statement Overview

Summary

Amplia Therapeutics Ltd. shows robust revenue growth but struggles with profitability, as reflected by negative EBIT and net profit margins. The balance sheet is stable with low leverage, but challenges persist in cash flow management, typical for early-stage biotech firms.

Income Statement

Amplia Therapeutics Ltd. has demonstrated strong revenue growth, with a substantial increase from last year. However, profitability remains a challenge, as evidenced by negative EBIT and net profit margins. The company continues to operate at a loss, which is typical in the biotechnology sector but requires attention for future sustainability.

Balance Sheet

The company's balance sheet shows a reasonable equity position with an equity ratio of 77%. However, the debt-to-equity ratio of 0.14 indicates some level of financial leverage. The balance sheet suggests stability, but the decrease in total assets and stockholders' equity over the past year may warrant careful monitoring.

Cash Flow

Cash flow analysis shows negative operating and free cash flow, which is concerning and typical for early-stage biotech firms. The operating cash flow to net income ratio suggests difficulty in generating positive cash flow relative to net losses. However, the company's ability to manage financing activities provides some level of mitigation.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	3.78M	3.78M	4.45M	1.19M	1.98M	1.53M
Gross Profit	3.57M	3.57M	4.01M	1.12M	1.98M	1.53M
EBITDA	-6.78M	-6.78M	-8.78M	-7.26M	-3.64M	-3.81M
Net Income	-6.57M	-6.57M	-4.50M	-6.24M	-3.64M	-2.28M
Balance Sheet
Total Assets	22.94M	22.94M	14.85M	18.68M	24.48M	10.88M
Cash, Cash Equivalents and Short-Term Investments	10.86M	10.86M	3.39M	9.26M	14.61M	1.85M
Total Debt	13.89K	13.89K	1.59M	2.27M	2.10M	0.00
Total Liabilities	1.91M	1.91M	3.43M	2.85M	2.64M	539.13K
Stockholders Equity	21.02M	21.02M	11.42M	15.84M	21.85M	10.34M
Cash Flow
Free Cash Flow	-6.89M	-6.89M	-5.13M	-5.31M	-4.42M	-2.92M
Operating Cash Flow	-6.89M	-6.89M	-5.13M	-5.29M	-4.40M	-2.92M
Investing Cash Flow	-2.07K	-2.07K	-2.23K	-58.42K	-26.64K	-5.35K
Financing Cash Flow	14.32M	14.32M	-772.98K	-84.22K	17.19M	3.66M

Amplia Therapeutics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.17
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:ATX, the sentiment is Positive. The current price of 0.17 is above the 20-day moving average (MA) of 0.16, below the 50-day MA of 0.18, and above the 200-day MA of 0.13, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 50.76 is Neutral, neither overbought nor oversold. The STOCH value of 61.11 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:ATX.

Amplia Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
1AD	46 Neutral	AU$3.07M	―	-628.72%	―	―	31.87%
AVE	46 Neutral	AU$14.28M	―	-143.71%	―	306.88%	―
ATX	45 Neutral	$84.66M	―	-41.60%	―	―	4.07%
NC6	40 Underperform	AU$17.34M	―	-1651.76%	―	-100.00%	2.86%
NOX	36 Underperform	AU$25.72M	―	-157.93%	―	―	-36.89%

Amplia Therapeutics Corporate Events

Amplia Therapeutics’ ACCENT Trial Shows Promising Results in Pancreatic Cancer Treatment

Amplia Therapeutics Ltd. presented interim data from its ACCENT trial at the AACR annual meeting, showcasing the promising efficacy of its FAK inhibitor, narmafotinib, in combination with chemotherapy for advanced pancreatic cancer. The data indicates that narmafotinib is well tolerated and shows better outcomes compared to chemotherapy alone, with a higher disease control rate and longer median duration on trial. This development could enhance Amplia’s positioning in the oncology market and provide new hope for stakeholders involved in pancreatic cancer treatment.

Amplia Therapeutics Launches US Trial for Innovative Pancreatic Cancer Treatment

Amplia Therapeutics Limited has initiated trial activities for a new pancreatic cancer treatment in the US, combining their FAK inhibitor narmafotinib with the chemotherapy FOLFIRINOX. The trial, managed by a multinational CRO, aims to assess the safety, tolerability, and efficacy of this combination in advanced pancreatic cancer patients, potentially enhancing treatment outcomes and strengthening Amplia’s position in the oncology field.

Amplia Therapeutics Reports Promising Data from Pancreatic Cancer Trial

Amplia Therapeutics has reported promising updated data from its ongoing ACCENT trial, which is evaluating the FAK inhibitor narmafotinib in combination with chemotherapy for advanced pancreatic cancer. The trial has shown encouraging efficacy with 13 confirmed partial responses and good tolerability, suggesting that narmafotinib may enhance the effectiveness of chemotherapy. This data will be presented at the American Association of Cancer Research Annual Meeting, highlighting the drug’s potential impact on pancreatic cancer treatment and reinforcing Amplia’s position in the oncology sector.

Amplia Therapeutics Advances US Clinical Trial Plans with FDA Approval

Amplia Therapeutics announced a positive outcome from its Type D meeting with the FDA regarding its planned clinical trial in the US for narmafotinib, a FAK inhibitor, in combination with FOLFIRINOX for advanced pancreatic cancer. The FDA’s approval of the proposed changes to the trial protocol allows Amplia to proceed with final planning stages, potentially positioning narmafotinib as a preferred drug in combination therapies for pancreatic cancer, enhancing its market position and offering promising prospects for stakeholders.

Amplia Therapeutics Adjusts Option Exercise Prices Post Capital Raising

Amplia Therapeutics Limited has announced a change in the exercise prices of its unlisted options following a successful A$13 million capital raising completed in December 2024. The adjustments, set to take effect on February 20, 2025, are in line with ASX Listing Rule 6.22.2 and will involve distributing replacement holding statements and application forms to all option holders, potentially impacting stakeholder engagement and financial strategies.